PTSD and stress sensitisation: a tale of brain and body Part 1: human studies.
Post-traumatic stress disorder (PTSD) is a chronic, debilitating psychiatric disorder that can follow exposure to extreme stressful experiences. It is characterised by hyperarousal and increased startle responses, re-experiencing of the traumatic event, withdrawal or avoidance behaviour and emotional numbing. The focus of this review is on aspects that have received less attention. PTSD develops only in a substantial minority of people exposed to traumatic stress, and possible individual traits that increase vulnerability are discussed. An overview is given of the wide variety of physiological disturbances that accompany PTSD and may contribute to disability, including neuroendocrine, cardiovascular, gastrointestinal and immune function and pain sensitivity. Brain imaging and pharmacological studies have generated some insight into the circuitry that may be involved in the generation of PTSD symptoms. Major limitations of human studies so far are the issue of causality and our lack of understanding of the underlying molecular substrates in the brain, which are easier to address in relevant animal models and will be discussed in a companion paper.
Stam
Rianne
R
Department of Pharmacology and Anatomy, Rudolf Magnus Institute of Neuroscience, Utrecht, the Netherlands. r.stam@med.uu.nl
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001245:Association Learning; D001921:Brain / Q000503:physiopathology*; D002320:Cardiovascular Physiological Phenomena; D006801:Humans; D009490:Neurosecretory Systems / Q000503:physiopathology*; D013216:Reflex, Startle; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D013315:Stress, Psychological / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents